HCV: The Journey from Discovery to a Cure

Chapter 43 The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa ® )

Chapter 44 Discovery of Elbasvir

Chapter 45 NS5A as a Target for HCV Drug Discovery

Chapter 46 Evolution of HCV NS4B Inhibitors

Chapter 47 The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex

Chapter 48 The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni ® )

Chapter 49 The Clinical Development of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX, Vosevi ® )

Chapter 50 HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments

Chapter 52 The Benefit of Direct-Acting Antiviral HCV Cure Therapies

Chapter 54 Development of ZEPATIER ®

Chapter 56 Cure and Control: What Will It Take to Eliminate HCV?

Chapter 60 Clinical Development of Viekira Pak to Mavyret

Chapter 63 Real-World Evidence and Hepatitis C

Chapter 65 Perspectives on HCV Cure

Chapter 66 The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni ®

Chapter 67 The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimens Epclusa and Vosevi ®